The psoriasis drug market is fiercely competitive, and strongly held by large pharmaceutical...
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Allergan assesses brazikumab in two clinical programmes for IBD
- AstraZeneca reports negative top-line results from TULIP 1 trial
- Arrowhead concludes dosing in Phase I ARO-AAT trial
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia
Lumoxiti (Moxetumomab pasudotox) is an investigational anti-CD22 recombinant immunotoxin developed as a potential treatment for relapsed/refractory hairy cell leukaemia (HCL) patients previously treated with at least two lines of therapy.
Aevi Genomic Medicine completes enrolment for Part B of ASCEND trial
Aevi Genomic Medicine has completed patient enrolment for Part B of its ASCEND clinical trial.
Tolero enrols first patient in Phase Ib/II trial of alvocidib
Tolero Pharmaceuticals has enrolled the first patient in its Phase Ib/II Zella 102 trial.
Roche reports positive data from trial of Kadcyla and Herceptin
Roche has reported positive results from the Phase III KATHERINE trial after meeting the study's primary endpoint.
September’s top news stories
Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma, and Ra Pharmaceuticals reported positive data from the Phase lb trial examining the pharmacokinetic (PK) of zilucoplan (RA101495 SC) to treat patients with renal impairment. Drugdevelopment-technology.com wraps up the key news stories from September 2018.
Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
French biopharmaceutical firm Poxel has concluded patient enrolment in the Phase III TIMES 2 clinical trial of its drug candidate Imeglimin for the treatment of type 2 diabetes in Japan.
Allergan assesses brazikumab in two clinical programmes for IBD
Allergan has commenced two clinical research programmes, INTREPID and EXPEDITION, to assess the safety and efficacy of its investigational IL-23 inhibitor therapy called brazikumab for inflammatory bowel disease (IBD).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.